GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » EBITDA Margin %

Scilex Holding Co (Scilex Holding Co) EBITDA Margin % : -209.62% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Scilex Holding Co's EBITDA for the three months ended in Mar. 2024 was $-22.82 Mil. Scilex Holding Co's Revenue for the three months ended in Mar. 2024 was $10.88 Mil. Therefore, Scilex Holding Co's EBITDA margin for the quarter that ended in Mar. 2024 was -209.62%.


Scilex Holding Co EBITDA Margin % Historical Data

The historical data trend for Scilex Holding Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co EBITDA Margin % Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-750.98 -130.22 -143.30 -25.75 -233.41

Scilex Holding Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -230.92 -203.55 -335.84 -147.13 -209.62

Competitive Comparison of Scilex Holding Co's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Scilex Holding Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's EBITDA Margin % falls into.



Scilex Holding Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Scilex Holding Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-109.104/46.743
=-233.41 %

Scilex Holding Co's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-22.815/10.884
=-209.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scilex Holding Co  (NAS:SCLX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Scilex Holding Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Scilex Holding Co (Scilex Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.
Executives
Sclx Stock Acquisition Jv Llc 10 percent owner 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma officer: Chief Financial Officer C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc. 10 percent owner 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji director, officer: Executive Chairperson 5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah director, officer: See Remarks C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak officer: See Remarks 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji director 25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint director C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632

Scilex Holding Co (Scilex Holding Co) Headlines

From GuruFocus